- Trials with a EudraCT protocol (115)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (3)
115 result(s) found for: Glioblastoma Multiforme.
Displaying page 4 of 6.
| EudraCT Number: 2013-004187-56 | Sponsor Protocol Number: HIT-HGG-2013 | Start Date*: 2017-04-24 | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Georg-August-Universität Göttingen, Stiftung Öffentlichen Rechts, Universitätsmedizin Göttingen | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: International cooperative Phase III trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents < ... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: First-line therapy of newly diagnosed, previously untreated high grade glioma, diffuse pontine glioma, and gliomatosis cerebri in children and adolescents <18 years. | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) AT (Completed) NL (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2009-011898-33 | Sponsor Protocol Number: HIT-HGG-CilMetro | Start Date*: 2011-11-28 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Martin-Luther-Universität Halle-Wittenberg | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents - A Phase II Study | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Treatment of relapsed or refractory high grade gliomas and diffuse intrinsic pontine gliomas in paediatric patients ≥ 3 years and < 18 years of age. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2007-000128-42 | Sponsor Protocol Number: HIT-HGG-2007 | Start Date*: 2009-03-19 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Martin-Luther-University Halle-Wittenberg | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: International cooperative Phase II trial of the HIT-HGG study group for the treatment of high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children ≥ 3 years and adole... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: 1st line therapy of newly diagnosed, previously untreated high grade glioma, diffuse intrinsic pontine glioma, and gliomatosis cerebri in children and adolescents ≥ 3 years and < 18 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Completed) AT (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2013-002200-13 | Sponsor Protocol Number: CBGJ398X2201 | Start Date*: 2014-05-09 | |||||||||||
| Sponsor Name:NOVARTIS FARMA S.p.A | |||||||||||||
| Full Title: A Phase 2, multicenter, open-label study of BGJ398 in patients with recurrent resectable or unresectable Glioblastoma | |||||||||||||
| Medical condition: recurrent resectable or unresectable Glioblastoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) NL (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2005-000459-14 | Sponsor Protocol Number: VUB/MedOnc/05-001 | Start Date*: 2007-07-02 |
| Sponsor Name:Oncologisch Centrum, Academisch Ziekenhuis Vrije Universiteit Brussel | ||
| Full Title: A Stratified Phase II Study of Cetuximab (ErbituxTM) for the Treatment of Recurrent Glioblastoma Multiforme / Estudio de fase II estratificado de cetuximab para el tratamiento del glioblastoma mult... | ||
| Medical condition: patients with a recurrent glioblastoma multiforme following preceding surgery, radiation therapy and chemotherapy | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2020-000310-15 | Sponsor Protocol Number: HC-MRI-GBM | Start Date*: 2020-03-26 | |||||||||||
| Sponsor Name:Christoffer Laustsen | |||||||||||||
| Full Title: MRI WITH HYPERPOLARISED PYRUVATE IN GLIOBLASTOMA – A PHASE II STUDY | |||||||||||||
| Medical condition: Glioblastoma multiforme | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DK (Trial now transitioned) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2020-003733-38 | Sponsor Protocol Number: ORP-TMZ-I-b | Start Date*: 2021-11-27 | |||||||||||||||||||||||||||||||
| Sponsor Name:ORPHELIA Pharma | |||||||||||||||||||||||||||||||||
| Full Title: TEMOkids study (ORP-TMZ-I- b): A Population pharmacokinetic, acceptability and safety study for KIMOZO, a paediatric oral suspension of temozolomide | |||||||||||||||||||||||||||||||||
| Medical condition: Different pediatric cancers such as malignant glioma and also relapsed or refractory neuroblastoma, rhabdomyosarcoma, medulloblastoma, and Ewing sarcoma, for which treatment with the cytotoxic tem... | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) NL (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2013-001550-98 | Sponsor Protocol Number: C-GBM(XRP6258) | Start Date*: 2013-10-04 |
| Sponsor Name:University Hospital of Ulm | ||
| Full Title: Prospective controlled phase 2 trial of cabazitaxel in patients with temozolomide refractory glioblastoma multiforme (GBM) - The C-GBM Study - | ||
| Medical condition: •Patients with diagnosis glioblastoma multiforme (GBM) WHO grade IV ; •Progression during or within 6 months after last temozolomide treatment; •Time since last temozolomide > 21 days | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Prematurely Ended) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2006-002606-54 | Sponsor Protocol Number: 8/2006 | Start Date*: 2006-03-02 | |||||||||||
| Sponsor Name:ASL SALERNO 1 | |||||||||||||
| Full Title: Investigational use of 5-ALA for fluorescence-guided resection of malignant glioma | |||||||||||||
| Medical condition: Glioblastoma multiforme | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-004627-18 | Sponsor Protocol Number: H6Q-MC-JCBF | Start Date*: 2006-08-04 |
| Sponsor Name:Eli Lilly and Company limited | ||
| Full Title: A Randomized Phase 3 Study of Enzastaurin versus Lomustine in the Treatment of Recurrent, Intracranial Glioblastoma Multiforme | ||
| Medical condition: Gliblastoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) ES (Completed) DE (Completed) BE (Completed) GB (Prematurely Ended) IT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-003722-41 | Sponsor Protocol Number: IOV–GB–1-2014-REGOMA | Start Date*: 2015-04-24 | |||||||||||
| Sponsor Name:Istituto Oncologico Veneto – IOV‐IRCCS | |||||||||||||
| Full Title: Regorafenib in relapsed glioblastoma. REGOMA study Randomized, controlled open‐label phase II clinical trial | |||||||||||||
| Medical condition: Glioblastoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2012-001049-42 | Sponsor Protocol Number: | Start Date*: 2012-07-05 |
| Sponsor Name:Department of Oncology, Rigshospitalet | ||
| Full Title: MRI-perfusion and FLT- and FET-PET during bevacizumab monotherapy for patients with recurrent Glioblastoma Multiforme | ||
| Medical condition: Recurrent Glioblastoma multiforme | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DK (Prematurely Ended) | ||
| Trial results: View results | ||
| EudraCT Number: 2006-001375-38 | Sponsor Protocol Number: RNOP-09 | Start Date*: 2006-08-30 |
| Sponsor Name:Klinik und Poliklinik für Neurologie der Universität Regensburg am Bezirksklinikum | ||
| Full Title: Temozolomide and pegylated (PEG)-liposomal Doxorubicin in first line treatment of patients with Glioblastoma WHO Grad IV | ||
| Medical condition: newly diagnosed Glioblastoma multiforme WHO Grade IV | ||
| Disease: | ||
| Population Age: Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2006-002881-20 | Sponsor Protocol Number: HGG-2006 | Start Date*: 2006-08-17 |
| Sponsor Name:University Hospital Gasthuisberg | ||
| Full Title: HGG-2006: a phase I/II clinical trial for the treatment of newly diagnosed high grade glioma with tumor vaccination as "add-on therapy" to standard primary treatment | ||
| Medical condition: Adults with newly diagnosed glioblastoma multiforme | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: BE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2022-001453-23 | Sponsor Protocol Number: G-85974806 | Start Date*: 2023-01-12 |
| Sponsor Name:ASATE | ||
| Full Title: Pilot safety study of neoadjuvant radiotherapy in patients with glioblastoma. | ||
| Medical condition: Glioblastoma | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: ES (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2008-003905-15 | Sponsor Protocol Number: GLITEM08 | Start Date*: 2008-07-29 | |||||||||||
| Sponsor Name:ISTITUTO NEUROLOGICO "CARLO BESTA" | |||||||||||||
| Full Title: Carmustine implant (Gliadel Wafer) plus adjuvant and concomitant Temozolomide in combination with radiotherapy in primary glioblastoma patients. | |||||||||||||
| Medical condition: glioblastoma recurrent | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2008-001645-26 | Sponsor Protocol Number: TMZ-FTM.CB.1 | Start Date*: 2008-06-01 | |||||||||||
| Sponsor Name:ISTITUTO NEUROLOGICO "CARLO BESTA" | |||||||||||||
| Full Title: Phase II study: Systemic treatment with alternating weekly regimen of temozolomide and monthly fotemustine combination in recurrent glioblastoma patients. | |||||||||||||
| Medical condition: Glioblastoma recurrent | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2007-000281-21 | Sponsor Protocol Number: H6Q-MC-S039 | Start Date*: 2007-09-05 | |||||||||||
| Sponsor Name:Eli Lilly and Company | |||||||||||||
| Full Title: Enzastaurin (LY317615) Before and Concomitant with Radiation Therapy, Followed by Enzastaurin Maintenance Therapy in Patients with Newly Diagnosed Glioblastoma without Methylation of the Promoter G... | |||||||||||||
| Medical condition: primary glioma without methylation of the promoter gene of MGMT enzyme | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-005644-24 | Sponsor Protocol Number: BERTES-01 | Start Date*: 2007-11-27 | |||||||||||||||||||||
| Sponsor Name:AMC-UvA | |||||||||||||||||||||||
| Full Title: Bevacizumab, Radiotherapy and Temozolomide Safety study in resected and irresectable primary GBM patients | |||||||||||||||||||||||
| Medical condition: Primary Glioblastoma Multiforme | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2014-004438-24 | Sponsor Protocol Number: M14-483 | Start Date*: 2015-06-23 | ||||||||||||||||
| Sponsor Name:AbbVie Deutschland GmbH & Co. KG | ||||||||||||||||||
| Full Title: INTELLANCE 2: ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group. | ||||||||||||||||||
| Medical condition: Glioblastoma Multiforme For Pediatric - High Grade Glioma and DIPG | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: NL (Completed) DE (Completed) HU (Completed) AT (Completed) FI (Completed) GB (Completed) IE (Completed) ES (Prematurely Ended) BE (Completed) CZ (Completed) FR (Completed) PL (Completed) IT (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
